Spinal Bulbar Muscular Atrophy Treatment Market Forecast to 2027 - COVID-19 Impact and Global Analysis by Drug Class (5- -Reductase Inhibitors (5-ARIs), Gonadotropin-releasing Hormone (GnRH) Agonists); Distribution Channel (Hospitals, Orthopedic Clinics, Ambulatory Surgical Centers) and Geography

Report Code: TIPRE00013514 | No. of Pages: 150 | Category: Pharmaceuticals | Status: Upcoming
Covid
MARKET INTRODUCTION

Spinal and bulbar muscular atrophy is also known as Kennedy disease. It is an ailment of the nerve cells that control muscle action. These nerve cells are located in the brainstem. Spinal and bulbar muscular atrophy mainly happens in males and is characterized by atrophy that usually appears in adulthood. Spinal and bulbar muscular atrophy causes cramping and weakness in leg muscle. The bulbar muscles are also hit, which causes disruptive difficulties in swallowing and speech. Fasciculation's, unusual breast enlargement, and infertility are also observed in this disorder.

MARKET DYNAMICS

The Spinal Bulbar Muscular Atrophy Treatment market is growing due to the rise in incidences of spinal bulbar muscular atrophy, and low cost of procedure also favorable reimbursement scenario. However, low availability of treatment drugs are expected to hamper the growth of the global Spinal Bulbar Muscular Atrophy Treatment market.

MARKET SCOPE

The "Spinal Bulbar Muscular Atrophy Treatment Market Analysis to 2027" is a specialized and in-depth study of the healthcare industry with a special focus on the global market trend analysis. The report aims to provide an overview of Spinal Bulbar Muscular Atrophy Treatment market with detailed market segmentation by drug class and distribution channel. The Spinal Bulbar Muscular Atrophy Treatment market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading players in Spinal Bulbar Muscular Atrophy Treatment market and offers key trends and opportunities in the market.

MARKET SEGMENTATION

The Spinal Bulbar Muscular Atrophy Treatment market is segmented on the basis of drug class and distribution channel. Based on drug class, the market is segmented as 5?-Reductase Inhibitors (5-ARIs), and Gonadotropin-releasing Hormone (GnRH) Agonists. On the basis of distribution channel, the market is categorized as Hospitals, and Orthopedic Clinics and Ambulatory Surgical Centers.

REGIONAL FRAMEWORK

The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the Spinal Bulbar Muscular Atrophy Treatment market based on various segments. It also provides market size and forecast estimates from year 2017 to 2027 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The Spinal Bulbar Muscular Atrophy Treatment market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.

The report analyzes factors affecting Spinal Bulbar Muscular Atrophy Treatment market from both demand and supply side and further evaluates market dynamics affecting the market during forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the Spinal Bulbar Muscular Atrophy Treatment market in these regions.



Get more information on this report :

MARKET PLAYERS


The report covers key developments in the Spinal Bulbar Muscular Atrophy Treatment market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market players from Spinal Bulbar Muscular Atrophy Treatment market are anticipated to have lucrative growth opportunities in the future with the rising demand for Spinal Bulbar Muscular Atrophy Treatment in the global market. Below mentioned is the list of few companies engaged in the Spinal Bulbar Muscular Atrophy Treatment market.

The report also includes the profiles of key players in Spinal Bulbar Muscular Atrophy Treatment market along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.

  •  GlaxoSmithKline plc.
  •  AbbVie Inc.
  •  Takeda Pharmaceutical Company Limited
  •  Century Pharmaceuticals Ltd
  •  Johnson & Johnson
  •  Astellas Pharma
  •  Pfizer Inc.
  •  Boehringer Ingelheim International GmbH
  •  Sanofi.
  •  Novartis

The Insight Partner's dedicated research and analysis team consists of experienced professionals with advanced statistical expertise and offers various customization options in the existing study.


Get more information on this report :

TABLE OF CONTENTS

1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Spinal Bulbar Muscular Atrophy Treatment Market - By Drug Class
1.3.2 Spinal Bulbar Muscular Atrophy Treatment Market - By Distribution Channel
1.3.3 Spinal Bulbar Muscular Atrophy Treatment Market - By Region
1.3.3.1 By Country

2. KEY TAKEAWAYS

3. RESEARCH METHODOLOGY

4. SPINAL BULBAR MUSCULAR ATROPHY TREATMENT MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS

5. SPINAL BULBAR MUSCULAR ATROPHY TREATMENT MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS

6. SPINAL BULBAR MUSCULAR ATROPHY TREATMENT MARKET - GLOBAL MARKET ANALYSIS
6.1. SPINAL BULBAR MUSCULAR ATROPHY TREATMENT - GLOBAL MARKET OVERVIEW
6.2. SPINAL BULBAR MUSCULAR ATROPHY TREATMENT - GLOBAL MARKET AND FORECAST TO 2027
6.3. MARKET POSITIONING/MARKET SHARE

7. SPINAL BULBAR MUSCULAR ATROPHY TREATMENT MARKET - REVENUE AND FORECASTS TO 2027 - DRUG CLASS
7.1. OVERVIEW
7.2. DRUG CLASS MARKET FORECASTS AND ANALYSIS
7.3. 5- -REDUCTASE INHIBITORS (5-ARIS)
7.3.1. Overview
7.3.2. 5- -Reductase Inhibitors (5-ARIs) Market Forecast and Analysis
7.4. GONADOTROPIN-RELEASING HORMONE (GNRH) AGONISTS
7.4.1. Overview
7.4.2. Gonadotropin-releasing Hormone (GnRH) Agonists Market Forecast and Analysis
8. SPINAL BULBAR MUSCULAR ATROPHY TREATMENT MARKET - REVENUE AND FORECASTS TO 2027 - DISTRIBUTION CHANNEL
8.1. OVERVIEW
8.2. DISTRIBUTION CHANNEL MARKET FORECASTS AND ANALYSIS
8.3. HOSPITALS
8.3.1. Overview
8.3.2. Hospitals Market Forecast and Analysis
8.4. ORTHOPEDIC CLINICS
8.4.1. Overview
8.4.2. Orthopedic Clinics Market Forecast and Analysis
8.5. AMBULATORY SURGICAL CENTERS
8.5.1. Overview
8.5.2. Ambulatory Surgical Centers Market Forecast and Analysis

9. SPINAL BULBAR MUSCULAR ATROPHY TREATMENT MARKET REVENUE AND FORECASTS TO 2027 - GEOGRAPHICAL ANALYSIS
9.1. NORTH AMERICA
9.1.1 North America Spinal Bulbar Muscular Atrophy Treatment Market Overview
9.1.2 North America Spinal Bulbar Muscular Atrophy Treatment Market Forecasts and Analysis
9.1.3 North America Spinal Bulbar Muscular Atrophy Treatment Market Forecasts and Analysis - By Drug Class
9.1.4 North America Spinal Bulbar Muscular Atrophy Treatment Market Forecasts and Analysis - By Distribution Channel
9.1.5 North America Spinal Bulbar Muscular Atrophy Treatment Market Forecasts and Analysis - By Countries
9.1.5.1 United States Spinal Bulbar Muscular Atrophy Treatment Market
9.1.5.1.1 United States Spinal Bulbar Muscular Atrophy Treatment Market by Drug Class
9.1.5.1.2 United States Spinal Bulbar Muscular Atrophy Treatment Market by Distribution Channel
9.1.5.2 Canada Spinal Bulbar Muscular Atrophy Treatment Market
9.1.5.2.1 Canada Spinal Bulbar Muscular Atrophy Treatment Market by Drug Class
9.1.5.2.2 Canada Spinal Bulbar Muscular Atrophy Treatment Market by Distribution Channel
9.1.5.3 Mexico Spinal Bulbar Muscular Atrophy Treatment Market
9.1.5.3.1 Mexico Spinal Bulbar Muscular Atrophy Treatment Market by Drug Class
9.1.5.3.2 Mexico Spinal Bulbar Muscular Atrophy Treatment Market by Distribution Channel
9.2. EUROPE
9.2.1 Europe Spinal Bulbar Muscular Atrophy Treatment Market Overview
9.2.2 Europe Spinal Bulbar Muscular Atrophy Treatment Market Forecasts and Analysis
9.2.3 Europe Spinal Bulbar Muscular Atrophy Treatment Market Forecasts and Analysis - By Drug Class
9.2.4 Europe Spinal Bulbar Muscular Atrophy Treatment Market Forecasts and Analysis - By Distribution Channel
9.2.5 Europe Spinal Bulbar Muscular Atrophy Treatment Market Forecasts and Analysis - By Countries
9.2.5.1 Germany Spinal Bulbar Muscular Atrophy Treatment Market
9.2.5.1.1 Germany Spinal Bulbar Muscular Atrophy Treatment Market by Drug Class
9.2.5.1.2 Germany Spinal Bulbar Muscular Atrophy Treatment Market by Distribution Channel
9.2.5.2 France Spinal Bulbar Muscular Atrophy Treatment Market
9.2.5.2.1 France Spinal Bulbar Muscular Atrophy Treatment Market by Drug Class
9.2.5.2.2 France Spinal Bulbar Muscular Atrophy Treatment Market by Distribution Channel
9.2.5.3 Italy Spinal Bulbar Muscular Atrophy Treatment Market
9.2.5.3.1 Italy Spinal Bulbar Muscular Atrophy Treatment Market by Drug Class
9.2.5.3.2 Italy Spinal Bulbar Muscular Atrophy Treatment Market by Distribution Channel
9.2.5.4 Spain Spinal Bulbar Muscular Atrophy Treatment Market
9.2.5.4.1 Spain Spinal Bulbar Muscular Atrophy Treatment Market by Drug Class
9.2.5.4.2 Spain Spinal Bulbar Muscular Atrophy Treatment Market by Distribution Channel
9.2.5.5 United Kingdom Spinal Bulbar Muscular Atrophy Treatment Market
9.2.5.5.1 United Kingdom Spinal Bulbar Muscular Atrophy Treatment Market by Drug Class
9.2.5.5.2 United Kingdom Spinal Bulbar Muscular Atrophy Treatment Market by Distribution Channel
9.3. ASIA-PACIFIC
9.3.1 Asia-Pacific Spinal Bulbar Muscular Atrophy Treatment Market Overview
9.3.2 Asia-Pacific Spinal Bulbar Muscular Atrophy Treatment Market Forecasts and Analysis
9.3.3 Asia-Pacific Spinal Bulbar Muscular Atrophy Treatment Market Forecasts and Analysis - By Drug Class
9.3.4 Asia-Pacific Spinal Bulbar Muscular Atrophy Treatment Market Forecasts and Analysis - By Distribution Channel
9.3.5 Asia-Pacific Spinal Bulbar Muscular Atrophy Treatment Market Forecasts and Analysis - By Countries
9.3.5.1 Australia Spinal Bulbar Muscular Atrophy Treatment Market
9.3.5.1.1 Australia Spinal Bulbar Muscular Atrophy Treatment Market by Drug Class
9.3.5.1.2 Australia Spinal Bulbar Muscular Atrophy Treatment Market by Distribution Channel
9.3.5.2 China Spinal Bulbar Muscular Atrophy Treatment Market
9.3.5.2.1 China Spinal Bulbar Muscular Atrophy Treatment Market by Drug Class
9.3.5.2.2 China Spinal Bulbar Muscular Atrophy Treatment Market by Distribution Channel
9.3.5.3 India Spinal Bulbar Muscular Atrophy Treatment Market
9.3.5.3.1 India Spinal Bulbar Muscular Atrophy Treatment Market by Drug Class
9.3.5.3.2 India Spinal Bulbar Muscular Atrophy Treatment Market by Distribution Channel
9.3.5.4 Japan Spinal Bulbar Muscular Atrophy Treatment Market
9.3.5.4.1 Japan Spinal Bulbar Muscular Atrophy Treatment Market by Drug Class
9.3.5.4.2 Japan Spinal Bulbar Muscular Atrophy Treatment Market by Distribution Channel
9.3.5.5 South Korea Spinal Bulbar Muscular Atrophy Treatment Market
9.3.5.5.1 South Korea Spinal Bulbar Muscular Atrophy Treatment Market by Drug Class
9.3.5.5.2 South Korea Spinal Bulbar Muscular Atrophy Treatment Market by Distribution Channel
9.4. MIDDLE EAST AND AFRICA
9.4.1 Middle East and Africa Spinal Bulbar Muscular Atrophy Treatment Market Overview
9.4.2 Middle East and Africa Spinal Bulbar Muscular Atrophy Treatment Market Forecasts and Analysis
9.4.3 Middle East and Africa Spinal Bulbar Muscular Atrophy Treatment Market Forecasts and Analysis - By Drug Class
9.4.4 Middle East and Africa Spinal Bulbar Muscular Atrophy Treatment Market Forecasts and Analysis - By Distribution Channel
9.4.5 Middle East and Africa Spinal Bulbar Muscular Atrophy Treatment Market Forecasts and Analysis - By Countries
9.4.5.1 South Africa Spinal Bulbar Muscular Atrophy Treatment Market
9.4.5.1.1 South Africa Spinal Bulbar Muscular Atrophy Treatment Market by Drug Class
9.4.5.1.2 South Africa Spinal Bulbar Muscular Atrophy Treatment Market by Distribution Channel
9.4.5.2 Saudi Arabia Spinal Bulbar Muscular Atrophy Treatment Market
9.4.5.2.1 Saudi Arabia Spinal Bulbar Muscular Atrophy Treatment Market by Drug Class
9.4.5.2.2 Saudi Arabia Spinal Bulbar Muscular Atrophy Treatment Market by Distribution Channel
9.4.5.3 U.A.E Spinal Bulbar Muscular Atrophy Treatment Market
9.4.5.3.1 U.A.E Spinal Bulbar Muscular Atrophy Treatment Market by Drug Class
9.4.5.3.2 U.A.E Spinal Bulbar Muscular Atrophy Treatment Market by Distribution Channel
9.5. SOUTH AND CENTRAL AMERICA
9.5.1 South and Central America Spinal Bulbar Muscular Atrophy Treatment Market Overview
9.5.2 South and Central America Spinal Bulbar Muscular Atrophy Treatment Market Forecasts and Analysis
9.5.3 South and Central America Spinal Bulbar Muscular Atrophy Treatment Market Forecasts and Analysis - By Drug Class
9.5.4 South and Central America Spinal Bulbar Muscular Atrophy Treatment Market Forecasts and Analysis - By Distribution Channel
9.5.5 South and Central America Spinal Bulbar Muscular Atrophy Treatment Market Forecasts and Analysis - By Countries
9.5.5.1 Brazil Spinal Bulbar Muscular Atrophy Treatment Market
9.5.5.1.1 Brazil Spinal Bulbar Muscular Atrophy Treatment Market by Drug Class
9.5.5.1.2 Brazil Spinal Bulbar Muscular Atrophy Treatment Market by Distribution Channel
9.5.5.2 Argentina Spinal Bulbar Muscular Atrophy Treatment Market
9.5.5.2.1 Argentina Spinal Bulbar Muscular Atrophy Treatment Market by Drug Class
9.5.5.2.2 Argentina Spinal Bulbar Muscular Atrophy Treatment Market by Distribution Channel

10. INDUSTRY LANDSCAPE
10.1. MERGERS AND ACQUISITIONS
10.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
10.3. NEW PRODUCT LAUNCHES
10.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS

11. SPINAL BULBAR MUSCULAR ATROPHY TREATMENT MARKET, KEY COMPANY PROFILES
11.1. GLAXOSMITHKLINE PLC.
11.1.1. Key Facts
11.1.2. Business Description
11.1.3. Products and Services
11.1.4. Financial Overview
11.1.5. SWOT Analysis
11.1.6. Key Developments
11.2. ABBVIE INC.
11.2.1. Key Facts
11.2.2. Business Description
11.2.3. Products and Services
11.2.4. Financial Overview
11.2.5. SWOT Analysis
11.2.6. Key Developments
11.3. TAKEDA PHARMACEUTICAL COMPANY LIMITED
11.3.1. Key Facts
11.3.2. Business Description
11.3.3. Products and Services
11.3.4. Financial Overview
11.3.5. SWOT Analysis
11.3.6. Key Developments
11.4. CENTURY PHARMACEUTICALS LTD
11.4.1. Key Facts
11.4.2. Business Description
11.4.3. Products and Services
11.4.4. Financial Overview
11.4.5. SWOT Analysis
11.4.6. Key Developments
11.5. JOHNSON AND JOHNSON
11.5.1. Key Facts
11.5.2. Business Description
11.5.3. Products and Services
11.5.4. Financial Overview
11.5.5. SWOT Analysis
11.5.6. Key Developments
11.6. ASTELLAS PHARMA
11.6.1. Key Facts
11.6.2. Business Description
11.6.3. Products and Services
11.6.4. Financial Overview
11.6.5. SWOT Analysis
11.6.6. Key Developments
11.7. PFIZER INC.
11.7.1. Key Facts
11.7.2. Business Description
11.7.3. Products and Services
11.7.4. Financial Overview
11.7.5. SWOT Analysis
11.7.6. Key Developments
11.8. BOEHRINGER INGELHEIM INTERNATIONAL GMBH
11.8.1. Key Facts
11.8.2. Business Description
11.8.3. Products and Services
11.8.4. Financial Overview
11.8.5. SWOT Analysis
11.8.6. Key Developments
11.9. SANOFI
11.9.1. Key Facts
11.9.2. Business Description
11.9.3. Products and Services
11.9.4. Financial Overview
11.9.5. SWOT Analysis
11.9.6. Key Developments
11.10. NOVARTIS
11.10.1. Key Facts
11.10.2. Business Description
11.10.3. Products and Services
11.10.4. Financial Overview
11.10.5. SWOT Analysis
11.10.6. Key Developments

12. APPENDIX
12.1. ABOUT THE INSIGHT PARTNERS
12.2. GLOSSARY OF TERMS
The List of Companies

1. GlaxoSmithKline plc.
2. AbbVie Inc.
3. Takeda Pharmaceutical Company Limited
4. Century Pharmaceuticals Ltd
5. Johnson and Johnson
6. Astellas Pharma
7. Pfizer Inc.
8. Boehringer Ingelheim International GmbH
9. Sanofi
10. Novartis
TIPRE00013514
Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Pricing

Free

20%

customization on Pre-Booking